Clinical Trials Open To Enrollment
- An 18-month trial investigating an infusion-based medication (infusions done in clinic) which may target amyloid plaque in the brain. This study is for individuals with mild cognitive impairment. We also have a similar study for individuals with mild Alzheimer’s disease. For more information, please visit the study website.
- An 18-month trial investigating an oral medication (given once daily), which may inhibit a particular enzyme known to be part of the amyloid production process. This study is for individuals with mild to moderate Alzheimer’s disease. We also have a similar study with the same drug for individuals with mild cognitive impairment.
- An 8-month pilot study investigating coconut oil for individuals with mild to moderate Alzheimer’s disease. For more information. For more information, please see study flyer.
- A 1-year study investigating an oral medication drug that may benefit synaptic communications between brain cells.
- A 3 ½ - year prevention study in which participants may receive an amyloid-targeting treatment for individuals 65-85 years old who are at risk for Alzheimer’s disease (have a family history, test positive on an amyloid PET scan, etc) but currently have no memory problems. For more information, please view study flyer.
- A 4-month trial investigating an injection-based medication (given 5 days a week for 3 weeks) for individuals with mild to moderate Alzheimer’s disease. This particular medication is used for other conditions and stimulates the growth of white blood cells (which help your body fight against infection).
Our research partners at the USF School of Aging Studies are also enrolling in:
- A home-based monthly memory testing program for people who are 55 and older who currently have no memory problems. (Please note, no treatment is involved in this program.)
For more information about these and other clinical trials at the USF Health Byrd Alzheimer's Institute, please contact Jill Smith, MA, CCRC at (813) 974-1294 or email@example.com.